Finding routes to market in the NHS for innovative products

Finding routes to market in the NHS for innovative products2018-10-15T10:35:43+00:00

Project Description

Finding routes to market in the NHS for innovative products

The Client:

PolyPhotonix, a bio-photonic research and development company, designs, develops and manufactures non-invasive photonic based medical devices.  They have been researching causes and treatments of eye disease for over 6 years.

Diabetic Retinopathy is caused by changes in the blood vessels of the retina. New fragile blood vessels start to grow and often leak blood and fluid. 90% of people with Type 1 diabetes will develop Diabetic Retinopathy within 10 years. 67% of people with Type 2 diabetes will develop Diabetic Retinopathy within 10 years.

PolyPhotonix was new to working with the NHS. The company had developed a light therapy mask for the prevention andtreatment of diabetic retinopathy, a condition which costs the NHS more than £1 billion a year. Current treatment costs up to £10,000 per patient for each eye; the Polyphotonix sleep mask costs £250 for 12 weeks treatment.

The Problem:

PolyPhotonix needed help to find practitioners and patients for a clinical study into the efficacy of the Noctura 400 sleep mask,  a revolutionary treatment for diabetic retinopathy and diabetic macular oedema (DMO).

What we did:

Whilst working as Commercial Director for the SW AHSN Paula Varndell-Dawes assisted Polyphotonix to recruit local sites for their clinical study into Noctura 400 treatment for Diabetic Retinopathy to demonstrate and evaluate the care pathway for NHS adoption (CANDLE).

Paula was able to help with:

  • Introduction to the local Ophthalmology community, their assessment of the CANDLE protocol, and buy-in.
  • Recruitment of local PI’s with R&D support to participate in CANDLE.
  • Local NIHR introduction to support the CANDLE study recruitment, leading to site support and monitoring for on-‐time performance.
  • Interface and complimenting alignment with other supporting AHSN’s

What the client said:

“The AHSN has been absolutely instrumental in opening doors and getting us into the right places. It accelerates innovation and it’s accelerating the adoption of our technology into the NHS.”

Richard Kirk, Chief Executive, PolyPhototonix
Support from the AHSNs in Kent, Surrey and Sussex, North East and North Cumbria and the South West helped speed up the mask’s route to market by engaging clinicians, validating the market and supporting the faster completion of multiplecentre phase three randomised control trials.
PolyPhotonix now employs 30 staff and is creating a manufacturing facility in the north-east with a further 30 high-value jobs.

Do you have a similar project? Do you need our assistance?

One of our professional expert team members have the knowledge, skills and contacts to put you in the right place at the right time.
Schedule a Consultation Today!